Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
CellVax Therapeutics
AddedFeb 15, 2024
UpdatedJun 18, 2026
CellVax Therapeutics

CellVax Therapeutics

Series A

CellVax Therapeutics: A private, clinical-stage firm innovating autologous cancer immunotherapy vaccines.

HQ
Miami, FL, US
Founded
2020
Overview
Compare
Fundraising
Employees
Website

CellVax Therapeutics, a privately-held clinical-stage company, was founded with the mission to innovate in the field of cancer immunotherapy. The company's core vision is to develop personalized, autologous cancer vaccines that harness the body's immune system to fight cancer. Their lead product, FK-PC101, targets prostate cancer patients at high risk of recurrence post-prostatectomy. Utilizing proprietary technology, FK-PC101 creates Tumor Presenting Cells (TPC) from the patient's own cancer cells to induce a multi-neoantigen immune response against cancer cells.

Notable figures associated with CellVax Therapeutics include Fernando Kreutz. The company has made significant strides in the development of FK-PC101, showcasing promising results in clinical trials. By focusing on personalized immunotherapy, CellVax Therapeutics aims to make a substantial impact on the treatment and management of cancer, potentially improving outcomes for patients with recurrent prostate cancer.

CellVax Therapeutics - Similar Companies

EpiVax Oncology logo

EpiVax Oncology

epivaxtx.com

Curevax logo

Curevax

Tvax Biomedical logo

Tvax Biomedical

Cancervax logo

Cancervax

cancervax.com

Agilvax logo

Agilvax

Ubivac logo

Ubivac

ubivac.com

Cell Vault logo

Cell Vault

cellvault.com

Imvax logo

Imvax

imvax.com

Photonpharma logo

Photonpharma

photonpharma.net

SapVax logo

SapVax

Cell BioEngines logo

Cell BioEngines

cellbioengines.com

Virion Therapeutics logo

Virion Therapeutics

viriontx.com

Imvaq Therapeutics logo

Imvaq Therapeutics

Geneos Therapeutics logo

Geneos Therapeutics

geneostx.com

Cellective BioTherapy logo

Cellective BioTherapy

CellVax Therapeutics - Quick Facts

Who are CellVax Therapeutics' competitors?

Companies similar to CellVax Therapeutics include EpiVax Oncology, Curevax, Tvax Biomedical and Cancervax.

When was CellVax Therapeutics founded?

CellVax Therapeutics was founded in 2020.

Where is CellVax Therapeutics' headquarters located?

CellVax Therapeutics' headquarters is located in Miami, FL, US.

When was CellVax Therapeutics' last funding round?

CellVax Therapeutics' most recent funding round was for $1.5M (USD) in April 2023.

How much has CellVax Therapeutics raised to-date?

As of Apr 4, 2023, CellVax Therapeutics has raised a total of $5.2M (USD).

How many employees does CellVax Therapeutics have?

CellVax Therapeutics has 2 employees as of Feb 4, 2024.

CellVax Therapeutics - Classification

Technology
  • Biotech
Geographic Exposure
  • Americas
Revenue
  • Recurring
Customer
  • Enterprise
Main Product
  • Cancer Vaccines
Tags
  • Healthtech
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 541000Professional, Scientific, and Technical Services
  • 541700Scientific Research and Development Services
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 8730Research, Development, And Testing Services
  • 8731Commercial Physical and Biological Research
Show 4 more industry codes
NAICS
  • 620000Health Care and Social Assistance
SIC
  • 8000Health Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified